secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2026-08-06T20:15:55+00:00
Accession:  0001193125-26-338068
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Surrozen reports Q2 2026 results; IND for SZN-8141 planned by Q3 end; PTAB denies Merck petition
--------------------------------------------------------------------------------

- Planned IND submission for SZN-8141 in DME by end of Q3 2026; DUET Phase 1b/2a to start by year-end 2026 with initial data in H2 2027.
- PTAB denied Merck's post-grant review petition challenging Surrozen's U.S. Patent No. 12,297,278, reinforcing IP position.
- Boehringer Ingelheim milestone triggered $5.0M collaboration revenue in Q2 2026 (vs $0 in Q2 2025).
- Cash and cash equivalents $102.0M as of June 30, 2026, down from $106.9M as of March 31, 2026.
- Net income $50.2M (including $59.6M non-cash gains) vs $39.7M (including $47.6M non-cash gains) in Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000119312526338068/0001193125-26-338068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000119312526338068/srzn-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-338068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer